Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
Hofheinz
R D
RD
Onkologisches Zentrum, III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Germany. ralf.hofheinz@med3.ma.uni-heidelberg.de
Dittrich
C
C
Jakupec
M A
MA
Drescher
A
A
Jaehde
U
U
Gneist
M
M
Graf von Keyserlingk
N
N
Keppler
B K
BK
Hochhaus
A
A
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000378:metabolism*; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics*; D015125:Oxyquinoline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D012958:Societies, Scientific
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C408502:tris(8-quinolinolato)gallium (III); D015125:Oxyquinoline